Because PTH1R, GLP-1R, and GCGR are well-known targets involved in regulating bone development and glucose metabolism and the genetic link between Lrp5/6 mutations and bone and metabolic disorders, we hypothesize that Lrp5/6 plays a role in mediating the β-catenin pathway induced by activation of these receptors. This evidence concerns the gene LRP5 and metabolic disease.